Minimed Group opens at $19.05, IPO at $20

Minimed Group opens at $19.05, IPO at $20

MiniMed Group’s (MMED) initial public offering (IPO) priced at $20.00 per share, raising $560 million through the sale of 28,000,000 shares. Trading on the Nasdaq began on March 6, 2026, with the stock opening at $19.05, below the IPO price. The offering is expected to close on March 9, 2026, subject to customary conditions. Underwriters retain a 30-day option to purchase up to 4,200,000 additional shares, which could increase total proceeds if exercised.

Following the IPO, Medtronic plc, MiniMed’s parent company, will retain approximately 90.03% ownership of MiniMed. This stake would reduce to 88.70% if the underwriters fully exercise the over-allotment option. Proceeds from the offering will fund general corporate purposes, with potential use to repay intercompany debt to Medtronic and cover costs related to asset transfers during MiniMed’s separation from its parent company.

Goldman Sachs & Co. LLC, BofA Securities, Citigroup, and Morgan Stanley are leading the offering as bookrunners, supported by additional joint managers and co-managers. The IPO marks a strategic step for MiniMed, a global leader in insulin delivery systems and continuous glucose monitoring technologies, as it seeks to strengthen its financial independence while maintaining ties to Medtronic.

Investors will closely monitor the stock’s performance following its debut, particularly given its initial trading price below the IPO level. The offering underscores ongoing trends in healthcare sector listings, where spinoffs and partial divestitures aim to unlock value while preserving operational synergies with parent organizations.